We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Circassia Group Plc | LSE:CIR | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 34.00 | 33.10 | 34.90 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
04/3/2019 12:22 | Shouldn't average down but have done a Woodford. My buys show as sells, just for info.Fingers crossed this isn't the basket case the share price reflects. | aspringo | |
22/2/2019 15:30 | Is it starting to creep up we will see! | bc4 | |
15/2/2019 13:30 | Lets hope so seems to be drifting again | bc4 | |
05/2/2019 12:18 | This is starting to look a good risk/reward play now. It has been plagued by main market funds having to dump it recently. The shares have been picked up by Woodford on Friday. By the 31st March , Azn and CIR have their joint development label for Duaklir, for approval by the US FDA . This is a significant date with a good chance of success. Clearly oversold. A short term target of 60p seems achievable hopefully imo. | miti 1000 | |
04/12/2018 14:55 | Nobody noticed the huge spike today on results? Impressive 27% rise but there are warnings of multiple risks associated with Brexit. This can't stay at these heady heights, surely? | yopf | |
23/10/2018 11:38 | I didnt see any RNS. Whats the news? | nitinkhattar | |
23/10/2018 08:31 | Looks like they misled investors Class action on cards | jammytass | |
12/7/2018 08:53 | For anyone wanting to find out more about Circassia there is a great article in the Telegraph today, lengthy interview with the CEO Steve Harris. Well worth a read to understand the potential here. | rathean | |
11/7/2018 15:14 | Talking to myself as usual... back in (again) at 82.97. | rathean | |
05/7/2018 14:36 | Back in today, looking for another bounce towards the top of its trading channel over the next week or two. | rathean | |
19/6/2018 13:35 | That's me in at 83.97, reached floor of slow rising channel. No guarantees with Trump on Twitter but happy to get in at this price. | rathean | |
26/4/2018 09:39 | I've got them on my watchlist, intriguing but high risk with huge cash burn and diminishing cash, although GSK investment mitigates that to some extent. Just not sure about this one, would welcome other opinions. | rathean | |
09/4/2018 14:12 | Does anyone actually follow this stock? Would be interested to hear your thoughts? | savagedstock | |
09/2/2018 11:23 | Just me, myself and I. So, apparently this is another Woodford hound high on the shorters list? Surely the recent big falls and curious auction buys at 75p suggest weighting now to the upside? | rathean | |
19/1/2018 15:34 | Wow, no one in here for 9 months :/ | rathean | |
18/4/2017 06:35 | Dead again. | bulltradept | |
17/3/2017 10:11 | From the DJN report - "The deal is expected to improve earnings for Circassia after one year and to be broadly cash neutral for three years, then cash generative." | bandflex | |
17/3/2017 09:51 | Silly me, I looked at that chart assumed AIM. | bandflex | |
17/3/2017 08:56 | Forget AIM. That's irrelevant to the investment case | mirabeau | |
17/3/2017 08:54 | Have to put it down to the vagaries of the AIM market. | bandflex | |
17/3/2017 08:51 | Your guess is as good as mine. it looks like a change in direction away from allergies. either way the market loves today's news and I bet the agreement suits both parties other than that, I am clueless... | mirabeau | |
17/3/2017 08:42 | It will cost CIR up to $230m, plus royalties, and Circassia will make R&D contributions of up to US$62.5 million payable to AstraZeneca as deferred payments. | bandflex | |
17/3/2017 08:40 | Interesting, but why is it going up. CIR are buying the rights from AStraZeneca to sell two AstraZeneca products not the other way around. | bandflex |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions